Intrinsic value of Wright Medical Group - WMGI

Previous Close

$28.72

  Intrinsic Value

$0.42

stock screener

  Rating & Target

str. sell

-99%

  Value-price divergence*

0%

Previous close

$28.72

 
Intrinsic value

$0.42

 
Up/down potential

-99%

 
Rating

str. sell

 
Value-price divergence*

0%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of WMGI stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2014), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2014(a)
   2015
   2016
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  23.14
  11.10
  10.49
  9.94
  9.45
  9.00
  8.60
  8.24
  7.92
  7.63
  7.36
  7.13
  6.91
  6.72
  6.55
  6.40
  6.26
  6.13
  6.02
  5.92
  5.82
  5.74
  5.67
  5.60
  5.54
  5.49
  5.44
  5.39
  5.35
  5.32
  5.29
Revenue, $m
  298
  331
  366
  402
  440
  480
  521
  564
  609
  655
  703
  753
  806
  860
  916
  975
  1,036
  1,099
  1,165
  1,234
  1,306
  1,381
  1,459
  1,541
  1,626
  1,716
  1,809
  1,906
  2,008
  2,115
  2,227
Variable operating expenses, $m
 
  716
  789
  865
  945
  1,029
  1,115
  1,206
  1,300
  1,397
  1,499
  1,585
  1,695
  1,809
  1,927
  2,050
  2,179
  2,312
  2,451
  2,596
  2,748
  2,905
  3,070
  3,242
  3,422
  3,609
  3,806
  4,011
  4,226
  4,450
  4,686
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  398
  716
  789
  865
  945
  1,029
  1,115
  1,206
  1,300
  1,397
  1,499
  1,585
  1,695
  1,809
  1,927
  2,050
  2,179
  2,312
  2,451
  2,596
  2,748
  2,905
  3,070
  3,242
  3,422
  3,609
  3,806
  4,011
  4,226
  4,450
  4,686
Operating income, $m
  -100
  -385
  -423
  -463
  -505
  -549
  -594
  -642
  -691
  -742
  -795
  -832
  -889
  -949
  -1,011
  -1,076
  -1,143
  -1,213
  -1,286
  -1,362
  -1,442
  -1,524
  -1,611
  -1,701
  -1,795
  -1,894
  -1,997
  -2,105
  -2,217
  -2,335
  -2,459
EBITDA, $m
  -71
  -350
  -387
  -425
  -465
  -507
  -551
  -596
  -644
  -693
  -744
  -797
  -852
  -909
  -969
  -1,030
  -1,095
  -1,162
  -1,232
  -1,305
  -1,381
  -1,460
  -1,543
  -1,629
  -1,720
  -1,814
  -1,913
  -2,016
  -2,124
  -2,237
  -2,355
Interest expense (income), $m
  7
  10
  12
  15
  17
  20
  23
  26
  29
  32
  35
  39
  43
  46
  50
  54
  58
  63
  67
  72
  77
  82
  88
  93
  99
  105
  112
  118
  125
  133
  140
Earnings before tax, $m
  -247
  -394
  -435
  -478
  -522
  -569
  -617
  -668
  -720
  -774
  -831
  -871
  -932
  -995
  -1,061
  -1,130
  -1,202
  -1,276
  -1,354
  -1,434
  -1,519
  -1,607
  -1,699
  -1,794
  -1,894
  -1,999
  -2,109
  -2,223
  -2,343
  -2,468
  -2,599
Tax expense, $m
  -6
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -260
  -394
  -435
  -478
  -522
  -569
  -617
  -668
  -720
  -774
  -831
  -871
  -932
  -995
  -1,061
  -1,130
  -1,202
  -1,276
  -1,354
  -1,434
  -1,519
  -1,607
  -1,699
  -1,794
  -1,894
  -1,999
  -2,109
  -2,223
  -2,343
  -2,468
  -2,599

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  230
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  893
  759
  839
  922
  1,010
  1,100
  1,195
  1,294
  1,396
  1,502
  1,613
  1,728
  1,848
  1,972
  2,101
  2,235
  2,375
  2,521
  2,672
  2,830
  2,995
  3,167
  3,347
  3,534
  3,730
  3,935
  4,149
  4,373
  4,607
  4,852
  5,108
Adjusted assets (=assets-cash), $m
  663
  759
  839
  922
  1,010
  1,100
  1,195
  1,294
  1,396
  1,502
  1,613
  1,728
  1,848
  1,972
  2,101
  2,235
  2,375
  2,521
  2,672
  2,830
  2,995
  3,167
  3,347
  3,534
  3,730
  3,935
  4,149
  4,373
  4,607
  4,852
  5,108
Revenue / Adjusted assets
  0.449
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
  0.436
Average production assets, $m
  142
  157
  174
  191
  209
  228
  248
  268
  289
  311
  334
  358
  383
  408
  435
  463
  492
  522
  553
  586
  620
  656
  693
  732
  773
  815
  859
  906
  954
  1,005
  1,058
Working capital, $m
  252
  25
  28
  31
  34
  37
  40
  43
  47
  50
  54
  58
  62
  66
  71
  75
  80
  85
  90
  95
  101
  106
  112
  119
  125
  132
  139
  147
  155
  163
  171
Total debt, $m
  281
  347
  419
  493
  572
  653
  738
  826
  918
  1,013
  1,112
  1,215
  1,322
  1,434
  1,549
  1,670
  1,795
  1,926
  2,061
  2,203
  2,351
  2,505
  2,666
  2,834
  3,009
  3,193
  3,384
  3,585
  3,795
  4,014
  4,244
Total liabilities, $m
  614
  680
  752
  826
  905
  986
  1,071
  1,159
  1,251
  1,346
  1,445
  1,548
  1,655
  1,767
  1,882
  2,003
  2,128
  2,259
  2,394
  2,536
  2,684
  2,838
  2,999
  3,167
  3,342
  3,526
  3,717
  3,918
  4,128
  4,347
  4,577
Total equity, $m
  279
  79
  87
  96
  105
  114
  124
  135
  145
  156
  168
  180
  192
  205
  218
  232
  247
  262
  278
  294
  312
  329
  348
  368
  388
  409
  431
  455
  479
  505
  531
Total liabilities and equity, $m
  893
  759
  839
  922
  1,010
  1,100
  1,195
  1,294
  1,396
  1,502
  1,613
  1,728
  1,847
  1,972
  2,100
  2,235
  2,375
  2,521
  2,672
  2,830
  2,996
  3,167
  3,347
  3,535
  3,730
  3,935
  4,148
  4,373
  4,607
  4,852
  5,108
Debt-to-equity ratio
  1.007
  4.400
  4.800
  5.140
  5.440
  5.710
  5.940
  6.140
  6.320
  6.480
  6.630
  6.760
  6.880
  6.990
  7.090
  7.180
  7.270
  7.350
  7.420
  7.480
  7.550
  7.600
  7.660
  7.710
  7.760
  7.800
  7.840
  7.880
  7.920
  7.960
  7.990
Adjusted equity ratio
  0.074
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104
  0.104

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -260
  -394
  -435
  -478
  -522
  -569
  -617
  -668
  -720
  -774
  -831
  -871
  -932
  -995
  -1,061
  -1,130
  -1,202
  -1,276
  -1,354
  -1,434
  -1,519
  -1,607
  -1,699
  -1,794
  -1,894
  -1,999
  -2,109
  -2,223
  -2,343
  -2,468
  -2,599
Depreciation, amort., depletion, $m
  29
  35
  36
  38
  40
  41
  43
  45
  47
  50
  52
  35
  38
  40
  43
  45
  48
  51
  54
  57
  61
  64
  68
  72
  76
  80
  84
  89
  94
  99
  104
Funds from operations, $m
  -128
  -360
  -399
  -440
  -483
  -527
  -574
  -622
  -672
  -725
  -779
  -836
  -894
  -955
  -1,019
  -1,085
  -1,153
  -1,225
  -1,299
  -1,377
  -1,458
  -1,542
  -1,631
  -1,723
  -1,819
  -1,919
  -2,024
  -2,134
  -2,249
  -2,369
  -2,495
Change in working capital, $m
  -12
  3
  3
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  6
  6
  6
  6
  7
  7
  7
  8
  8
  8
  9
Cash from operations, $m
  -116
  -362
  -402
  -443
  -486
  -530
  -577
  -625
  -676
  -728
  -783
  -839
  -898
  -959
  -1,023
  -1,089
  -1,158
  -1,230
  -1,304
  -1,382
  -1,463
  -1,548
  -1,637
  -1,729
  -1,825
  -1,926
  -2,031
  -2,142
  -2,257
  -2,378
  -2,504
Maintenance CAPEX, $m
  0
  -14
  -15
  -17
  -19
  -20
  -22
  -24
  -26
  -28
  -31
  -33
  -35
  -38
  -40
  -43
  -45
  -48
  -51
  -54
  -57
  -61
  -64
  -68
  -72
  -76
  -80
  -84
  -89
  -94
  -99
New CAPEX, $m
  -60
  -16
  -16
  -17
  -18
  -19
  -20
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -30
  -31
  -33
  -34
  -36
  -37
  -39
  -41
  -42
  -44
  -46
  -48
  -51
  -53
Cash from investing activities, $m
  146
  -30
  -31
  -34
  -37
  -39
  -42
  -44
  -47
  -50
  -54
  -57
  -60
  -64
  -67
  -71
  -74
  -78
  -82
  -87
  -91
  -97
  -101
  -107
  -113
  -118
  -124
  -130
  -137
  -145
  -152
Free cash flow, $m
  30
  -392
  -434
  -477
  -522
  -570
  -619
  -670
  -723
  -779
  -836
  -896
  -958
  -1,023
  -1,090
  -1,160
  -1,232
  -1,308
  -1,387
  -1,469
  -1,555
  -1,645
  -1,738
  -1,836
  -1,938
  -2,044
  -2,156
  -2,272
  -2,394
  -2,522
  -2,656
Issuance/(repayment) of debt, $m
  -4
  67
  71
  75
  78
  81
  85
  88
  92
  95
  99
  103
  107
  111
  116
  120
  125
  130
  136
  142
  148
  154
  161
  168
  175
  183
  192
  201
  210
  220
  230
Issuance/(repurchase) of shares, $m
  37
  402
  443
  486
  531
  578
  627
  678
  731
  785
  842
  883
  944
  1,008
  1,075
  1,144
  1,216
  1,291
  1,369
  1,451
  1,536
  1,625
  1,717
  1,814
  1,915
  2,020
  2,131
  2,246
  2,367
  2,493
  2,626
Cash from financing (excl. dividends), $m  
  33
  469
  514
  561
  609
  659
  712
  766
  823
  880
  941
  986
  1,051
  1,119
  1,191
  1,264
  1,341
  1,421
  1,505
  1,593
  1,684
  1,779
  1,878
  1,982
  2,090
  2,203
  2,323
  2,447
  2,577
  2,713
  2,856
Total cash flow (excl. dividends), $m
  59
  77
  81
  84
  87
  90
  93
  96
  99
  102
  105
  90
  93
  97
  101
  105
  109
  114
  118
  123
  129
  134
  140
  146
  153
  160
  167
  174
  183
  191
  200
Retained Cash Flow (-), $m
  181
  -402
  -443
  -486
  -531
  -578
  -627
  -678
  -731
  -785
  -842
  -883
  -944
  -1,008
  -1,075
  -1,144
  -1,216
  -1,291
  -1,369
  -1,451
  -1,536
  -1,625
  -1,717
  -1,814
  -1,915
  -2,020
  -2,131
  -2,246
  -2,367
  -2,493
  -2,626
Prev. year cash balance distribution, $m
 
  208
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  -117
  -362
  -402
  -444
  -488
  -534
  -582
  -632
  -683
  -737
  -793
  -851
  -911
  -974
  -1,039
  -1,107
  -1,178
  -1,251
  -1,328
  -1,407
  -1,491
  -1,577
  -1,668
  -1,762
  -1,861
  -1,964
  -2,072
  -2,184
  -2,302
  -2,426
Discount rate, %
 
  6.40
  6.72
  7.06
  7.41
  7.78
  8.17
  8.58
  9.01
  9.46
  9.93
  10.42
  10.95
  11.49
  12.07
  12.67
  13.31
  13.97
  14.67
  15.40
  16.17
  16.98
  17.83
  18.72
  19.66
  20.64
  21.67
  22.76
  23.89
  25.09
  26.34
PV of cash for distribution, $m
 
  -110
  -318
  -328
  -334
  -336
  -333
  -327
  -317
  -303
  -286
  -266
  -245
  -222
  -198
  -174
  -150
  -128
  -106
  -87
  -70
  -55
  -43
  -32
  -24
  -17
  -12
  -8
  -5
  -3
  -2
Current shareholders' claim on cash, %
  100
  48.8
  23.8
  11.7
  5.8
  2.8
  1.4
  0.7
  0.3
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Wright Medical Group N.V., a medical device company, designs, manufactures, markets, and sells extremities and biologics products.in the United States, Europe, the Middle East, Africa, and internationally. The company offers joint implants and bone fixation devices for the shoulder, elbow, wrist, hand, foot, and ankle; and biologics products that are used for supporting the treatment of damaged or diseased bones, tendons, and soft tissues, as well as to stimulate bone growth. It also provides sports medicines and other products to mechanically repair tissue-to-tissue or tissue-to-bone injuries. The company primarily offers its products to orthopedic, trauma, and podiatric surgeons. Wright Medical Group N.V. markets and sells its products through direct sales representatives and independent sales agencies in the United States; and direct sales offices and distributors in approximately 50 countries. The company was founded in 1999 and is headquartered in Amsterdam, the Netherlands.

FINANCIAL RATIOS  of  Wright Medical Group (WMGI)

Valuation Ratios
P/E Ratio -5.7
Price to Sales 4.9
Price to Book 5.3
Price to Tangible Book
Price to Cash Flow -12.7
Price to Free Cash Flow -8.4
Growth Rates
Sales Growth Rate 23.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 42.9%
Cap. Spend. - 3 Yr. Gr. Rate 4.1%
Financial Strength
Quick Ratio 230
Current Ratio 0.3
LT Debt to Equity 100.4%
Total Debt to Equity 100.7%
Interest Coverage -34
Management Effectiveness
Return On Assets -26.6%
Ret/ On Assets - 3 Yr. Avg. -17.6%
Return On Total Capital -40.2%
Ret/ On T. Cap. - 3 Yr. Avg. -25.2%
Return On Equity -70.4%
Return On Equity - 3 Yr. Avg. -41.7%
Asset Turnover 0.3
Profitability Ratios
Gross Margin 75.5%
Gross Margin - 3 Yr. Avg. 76.2%
EBITDA Margin -70.8%
EBITDA Margin - 3 Yr. Avg. -42.6%
Operating Margin -33.6%
Oper. Margin - 3 Yr. Avg. -48.3%
Pre-Tax Margin -82.9%
Pre-Tax Margin - 3 Yr. Avg. -59.8%
Net Profit Margin -87.2%
Net Profit Margin - 3 Yr. Avg. -66%
Effective Tax Rate 2.4%
Eff/ Tax Rate - 3 Yr. Avg. -6.4%
Payout Ratio 0%

WMGI stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the WMGI stock intrinsic value calculation we used $298 million for the last fiscal year's total revenue generated by Wright Medical Group. The default revenue input number comes from 2014 income statement of Wright Medical Group. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our WMGI stock valuation model: a) initial revenue growth rate of 11.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 6.4%, whose default value for WMGI is calculated based on our internal credit rating of Wright Medical Group, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Wright Medical Group.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of WMGI stock the variable cost ratio is equal to 216.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for WMGI stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Wright Medical Group.

Corporate tax rate of 27% is the nominal tax rate for Wright Medical Group. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the WMGI stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for WMGI are equal to 47.5%.

Life of production assets of 10.2 years is the average useful life of capital assets used in Wright Medical Group operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for WMGI is equal to 7.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $279 million for Wright Medical Group - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 52.18 million for Wright Medical Group is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Wright Medical Group at the current share price and the inputted number of shares is $1.5 billion.

RELATED COMPANIES Price Int.Val. Rating
RTIX RTI Surgical 4.65 1.53  str.sell
SYK Stryker 144.29 191.05  buy
ZBH Zimmer Biomet 111.38 49.95  str.sell
EXAC Exactech 29.95 3.92  str.sell
IART Integra LifeSc 50.22 21.13  str.sell
OFIX Orthofix Inter 48.00 40.63  hold
GMED Globus Medical 30.11 18.91  sell
NUVA NuVasive 64.06 66.59  hold
CFMS ConforMIS 3.47 0.56  str.sell

COMPANY NEWS

▶ Why Wright Medical Group Shares Are Spiking Higher Today   [Aug-03-17 01:40PM  Motley Fool]
▶ Wright Medical reports net loss, optimism for year ahead   [May-04-17 03:45PM  American City Business Journals]
▶ Wright Medical reports 1Q loss   [May-03-17 05:02PM  Associated Press]
▶ Wright Pops To Nearly 6-Year High On Strong Q4 Results, 2017 Outlook   [Feb-22-17 04:10PM  Investor's Business Daily]
▶ Wright Medical reports 4Q loss   [Feb-21-17 05:24PM  Associated Press]
Stock chart of WMGI Financial statements of WMGI
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.